<DOC>
	<DOCNO>NCT00959725</DOCNO>
	<brief_summary>The purpose study determine intravitreal infliximab safe effective treatment macular edema secondary diabetes .</brief_summary>
	<brief_title>Pilot Study Evaluation Intravitreal Infliximab Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>Participants diabetic macular edema treat one injection intravitreal infliximab ( 2.0mg/0.05ml ) follow three month . Outcomes assessed include best-corrected visual acuity , macular thickness measure optical coherence tomography , electroretinogram response .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Participant must 18 year age old . 2 . Participant DME amenable treatment laser photocoagulation refractory laser photocoagulation . 3 . Participant must negative PPD skin test . 4 . Participant must understand sign protocol 's informed consent document . 5 . Participants must DME define follow criterion : 1 . Presence diabetes ( type I type II ) 2 . Macular edema define central macular thickness ≥ 250μm OCT. 6 . Participant must visual acuity 20/40 hand motion study eye . 7 . Participant must steady fixation study eye medium clear enough good quality imaging . 8 . Female participant childbearing potential must pregnant breastfeeding , must negative pregnancy test screening must practice adequate method birth control . Males able father child must agree practice birth control . Acceptable method birth control include hormonal contraception ( birth control pill , inject hormone vaginal ring ) , intrauterine device , barrier method spermicide ( diaphragm spermicide , condom spermicide ) surgical sterilization ( hysterectomy , tubal ligation vasectomy partner ) . If participant childbearing potential , must willing undergo monthly urine pregnancy test . Both male female must agree use adequate birth control three month intravitreal infliximab injection . If eye participant qualify inclusion , eye bad visual acuity choose . 1 . Participant another investigational study actively receive study therapy . 2 . Participant proliferative diabetic retinopathy . 3 . Participant unable comply study procedure followup visit . 4 . Participant multiple sclerosis symptom suggestive multiple sclerosis . 5 . Participant evidence ocular disease DME either eye may confound outcome study ( e.g. , uveitis , agerelated macular degeneration , vitreomacular traction , moderate/severe myopia , etc. ) . 6 . Participant expect need ocular surgery panretinal photocoagulation study eye course study . 7 . Participant undergone ocular surgery intravitreal/periocular steroid injection study eye within past 3 month . 8 . Participant YAG laser capsulotomy intravitreal antiVEGF treatment study eye within past 6 week . 9 . Participant par plana vitrectomy study eye . 10 . Participant ocular systemic medication know toxic lens , retina , optic nerve . 11 . Participant history ocular herpes simplex virus infection study eye . 12 . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure glycemic control ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Macular Edema</keyword>
</DOC>